Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy
Magdalena Rudzińska,1 Cenk Daglioglu,2 Lyudmila V Savvateeva,1 Fatma Necmiye Kaci,3 Rodolphe Antoine,4 Andrey A Zamyatnin Jr1,5,6 1Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow 119991, Russia; 2Biotechnology and Bioengineering Application and Research Center...
Saved in:
Main Authors: | Rudzińska M (Author), Daglioglu C (Author), Savvateeva LV (Author), Kaci FN (Author), Antoine R (Author), Zamyatnin Jr AA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
by: Anastasiia I. Petushkova, et al.
Published: (2020) -
IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery
by: Amir R. Jalilian, et al.
Published: (2022) -
Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota
by: Michail Karavolos, et al.
Published: (2016) -
Nanosized Drug Delivery Systems: Colloids and Gels for Site Specific Targeting
Published: (2020) -
Nanosized Drug Delivery Systems to Fight Tuberculosis
by: Tom Bourguignon, et al.
Published: (2023)